# US 2001/0036932 A1 · Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0036932 A1
- Document ID: US20010036932A1
- Status: Published application
- Kind: A1
- Application number: 09/802,775
- Filed: 2001-03-09
- Published: 2001-11-01
- Earliest claimed: 2000-03-09
- Assignees: Intimax Corporation
- Inventors: Alan D. Cardin; Cornelius L. Van Gorp
- Web page: https://patentgrep.com/patent/US20010036932A1

## CPC

- A61K 31/42: Oxazoles
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.

## Claims

### Claim 1

A pharmaceutical combination, which comprises:
(a) a heparin cofactor II agonist; and
(b) a platelet GPIIb/IIIa receptor antagonist;
(c) the amount of a heparin cofactor II agonist and the amount of the platelet GPIIb/IIIa receptor antagonist combined being therapeutically effective to inhibit thrombin generation and platelet aggregation.

### Claim 2 (depends on 1)

The combination of claim 1 wherein heparin cofactor II agonist is a sulfated polysaccharide.

### Claim 3 (depends on 2)

The combination of claim 2 wherein the sulfated polysaccharide is dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units.

### Claim 4 (depends on 3)

The combination of claim 3 wherein he dermatan sulfate has more than about 50% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units.

### Claim 5 (depends on 3)

The combination of claim 3 wherein the dermatan sulfate has a molecular weight of from about 1,000 Daltons to about 60,000 Daltons.

### Claim 6 (depends on 5)

The combination of claim 5 wherein the dermatan sulfate has more than about 75% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units.

### Claim 7

The combination of wherein the dermatan sulfate has a molecular weight of from about 2,500 to about 37,500 Daltons.

### Claim 8 (depends on 3)

The combination of claim 3 wherein the platelet GPIIb/IIIa receptor antagonist is a cyclic heptapeptide selected from the group consisting of Mpr-(Acetimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH2, Mpr-(Acetimidyl-Lys)-Cly-Asp-Trp-Phe-Pen-NH2, Mpr-(Pheylimidly-Lys)-gly-asp-Trp-Phe-Pen-NH2, and Mpr-(Phenylimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH2, wherein Mpr is mercapto propionyl.

### Claim 9 (depends on 3)

The combination of claim 3 wherein the platelet GPIIb/IIIa receptor antagonist is selected from the group consisting of [3(R)-[2-piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-3(R)-methyl-b-alanine, 2(S)-[(p-toluenesulfonyl)amino]amino]-3-[[[5,6,7,8-etrahydro-4-oxo-5-[2-(piperidin-4-yl)ethyl]-4H-pyrazolo-[1,5-a][1,4]diazepin-2-yl]carbonyl]amino]propionic acid, 5-[(4-piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonyl-amino-b-alanine, 2-S-(n-butylsulfonylamino)-3[4-piperdin-4-yl)butyloxypheyl]propionic acid hydrochloride, (R)-methyl-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine monoacetate, xemlofiban, orbofiban, eptifibatide and mixtures thereof.

### Claim 10 (depends on 1)

The combination of claim 1 wherein the amount of at least one of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist is a subtherapeutic amount.

### Claim 11 (depends on 10)

The combination of claim 10 wherein the amount of each of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist is a subtherapeutic amount.

### Claim 12

A method for inhibiting platelet aggregation and thrombin generation, which comprises the step of administering to a mammal in need thereof a combined therapeutically effective amount of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist.

### Claim 13 (depends on 12)

The method of claim 12 wherein the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist are each administered as separate doses.

### Claim 14 (depends on 12)

The method of claim 12 wherein the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist are administered as a combined dose.

### Claim 15 (depends on 12)

The method of claim 12 wherein the amount administered of at least one of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist is a subtherapeutic amount.

### Claim 16 (depends on 15)

The method of claim 15 wherein the amount administered of each of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist is a subtherapeutic amount.

### Claim 17 (depends on 12)

The method of claim 12 wherein the heparin cofactor II agonist is a dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units and wherein the platelet glycoprotein IIB/IIIA receptor antagonist is selected from the group consisting Mpr-(Acetimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH2, Mpr-(Acetimidyl-Lys)-Cly-Asp-Trp-Phe-Pen-NH2, Mpr-(Pheylimidly-Lys)-gly-asp-Trp-Phe-Pen-NH2, and Mpr-(Phenylimidyl-Lys)-Gly-Asp-Trp-Phe-Cys-NH2, wherein Mpr is mercapto propionyl, [3(R)-[2-piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-3(R)-methyl-b-alanine, 2(S)-[(p-toluenesulfonyl)amino]amino]-3-[[[5,6,7,8-etrahydro-4-oxo-5-[2-(piperidin-4-yl)ethyl]-4H-pyrazolo-[1,5-a][1,4]diazepin-2-yl]carbonyl]-amino]propionic acid, 5-[(4-piperidinyl)methoxy]-2-indolecarbonyl-2(S)-phenylsulfonyl-amino-b-alanine, 2-S-(n-butylsulfonylamino)-3[4-piperdin-4-yl)butyloxypheyl]propionic acid hydrochloride, (R)-methyl-3-[[[3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine monoacetate, xemlofiban, orbofiban, eptifibatide and mixtures thereof.

### Claim 18 (depends on 17)

The method of claim 17 wherein the dermatan sulfate has more than about 75% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units.

### Claim 19 (depends on 12)

The method of claim 12 wherein the administration step comprises injecting the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist into the mammal.

### Claim 20 (depends on 19)

The method of claim 19 wherein the mammal is a human.
